WebMar 18, 2010 · High-dose cyclophosphamide is a highly immunosuppressive agent that, in addition to its successful use as a treatment for aplastic anemia 9-11 and other severe refractory autoimmune diseases, 14,16,21,22 has proven efficacy in allogeneic BMT as both a conditioning regimen 23 and graft-versus-host disease prophylaxis. 24 … WebCyclophosphamide induction regimens for antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis are effective in 70 to 90% of patients, but they are associated with high rates of death...
High-dose cyclophosphamide as single-agent, short-course prophylaxis …
WebPublished in 2009, CYCLOPS randomized 149 patients with newly-diagnosed ANCA vasculitis to pulse cyclophosphamide or daily oral cyclophosphamide. Both groups received corticosteroids and azathioprine. Despite its lower cumulative cyclophosphamide dose, pulse cyclophosphamide resulted in similar rates of remission as daily oral … WebT 0 Cyclophosphamide 1.5g/m2 in 500mL sodium chloride 0.9% IV infusion over 30-60 minutes. T 0 Mesna 0.3g/m2 IV bolus T +2 hours Mesna 0.6g/m2 PO T + 6 hours Mesna 0.6g/m2 PO Days 2 to 10 GCSF (filgrastim) SC Daily. Refer to: NSSG>BMT> B.36 Filgrastim-Biosimilar protocol Dose modifications dhea and adrenals
Rituximab versus Cyclophosphamide in ANCA …
WebIV Cyclophosphamide Protocols for Systemic Lupus Erythematosus. Disease Complication. Regimen [a] Lupus nephritis [b] Induction therapy for lupus nephritis: 500 … WebRecommended dosing schedule for the EUVAS protocol: Age (years) eGFR greater than 30 ml/min/1.73 m 2eGFR less than or equal to 30 ml/min/1.73 m Less than 60 15 mg/kg … WebCyclophosphamide, also called Cytoxan, is classified as a “cytotoxic agent”, because it has a toxic effect on many types of cells (“good” cells as well as “bad”). Cyclophosphamide … dhea and bipolar